Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/15/2021 | 04:21pm EST

Mirum Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 47.11 million compared to USD 21.51 million a year ago. Basic loss per share from continuing operations was USD 1.55 compared to USD 0.86 a year ago. For the nine months, net loss was USD 141.53 million compared to USD 66.07 million a year ago. Basic loss per share from continuing operations was USD 4.68 compared to USD 2.65 a year ago.


ę S&P Capital IQ 2021
All news about MIRUM PHARMACEUTICALS, INC.
01/28SVB Leerink Adjusts Mirum Pharmaceuticals' Price Target to $46 from $42, Keeps Outperfo..
MT
01/19CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Acc..
AQ
01/12Raymond James Adjusts Mirum Pharmaceuticals Price Target to $70 From $69, Maintains Str..
MT
01/11Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
01/11MIRUM PHARMACEUTICALS : Provides Business Update and Highlights Key 2022 Corporate Milesto..
PU
01/11MIRUM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD..
AQ
01/11Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milest..
BU
01/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/04Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference o..
BU
01/03Immix Biopharma Shares More Than Double on FDA Designation
DJ
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 78,4 M - -
Net income 2021 -129 M - -
Net cash 2021 127 M - -
P/E ratio 2021 -4,03x
Yield 2021 -
Capitalization 554 M 554 M -
EV / Sales 2021 5,43x
EV / Sales 2022 10,6x
Nbr of Employees 137
Free-Float 94,7%
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 18,16 $
Average target price 54,86 $
Spread / Average Target 202%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Chief Scientific Officer
Edwin J. Tucker Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.13.86%554
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892